MedTrace Logo

A Study of MSB0254 Injection in Advanced Solid Tumors

NCT04381325 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2023-04-05

No results posted yet for this study

Summary

This study was an open, multi-dose dose escalation phase I clinical study to evaluate the safety, tolerability and PK characteristics of MSB0254 in patients with locally advanced or metastatic solid tumors, and to preliminarily measure its anti-tumor efficacy.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

MSB0254 Injection

An intravenous infusion with concentration from 4 mg/kg to 16 mg/kg every 2 weeks (Q2W). An intravenous infusion with concentration 20 mg/kg every 3 weeks (Q3W).

Sponsors & Collaborators

  • Suzhou Transcenta Therapeutics Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Mengde Wang · Suzhou Transcenta Therapeutics Co., Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2022-06-08
Completion
2022-06-08

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04381325 on ClinicalTrials.gov